Navigation Links
New opportunities to treat bowel cancer
Date:7/8/2013

Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.

More than one million people develop bowel cancer each year, which is one of the most common causes of death in cancer patients. One in ten colon cancers are caused by mutations in the BRAF gene, a gene commonly associated with skin cancers. Although successful treatments against BRAF mutations in skin cancers have been developed, these treatments have not been effective against BRAF mutations in colon cancer.

"Our approach encapsulates the aim of cancer genomics: to discover changes to DNA responsible for cancer development and pinpoint the "Achilles heels" of cancer in order to identify new treatments," says Professor Roland Rad, lead author from the Technical University of Munich and the German Cancer Research Center. "Our studies in mice revealed how genes co-operate to cause a specific subset of colon cancers. We identified main players, the order in which they occur during tumour progression, and the molecular processes how they turn relatively benign cell growth into threatening cancers. Such processes are targets for new treatments."

The team looked at the development of BRAF associated bowel cancer in mice, replacing the normal gene with a version containing a mutation identical with that in human cancers. Mice with the mutated BRAF gene developed hyperplastic polyps abnormal growth of cell bundles in their intestine wall. These polyps progressed from benign growths to malignant cancers.

In the mutant mice, the team uncovered a stepwise process of genetic alterations, which drive the development of this type of colon cancer. Some alterations activate genes such a BRAF, making them potentially cancerous. Others disrupt protective proteins such as p53, inactivating their ability to suppress cancer progression.

"Understanding the genetic makeup of different colorectal cancer subtypes will guide therapeutic decision making in the future" says Professor Allan Bradley, senior author from the Wellcome Trust Sanger Institute. "Our ability to engineer specific genetic alterations in mice allows us to study the function of cancer genes and to model specific cancer subtypes at an organismal level. Such mouse models are also invaluable for testing anticancer drugs before using them in clinical trials".

The team tested a wide range of existing and candidate drugs for their ability to slow down or prevent growth of mouse colon cancer and human colon cancer cells, finding several highly effective approaches. These were tested individually or in combination with one another to find the most powerful therapies.

Mice with the Braf-associated colon cancer had very similar therapeutic responses to those of BRAF-associated cancer cells from patients with colon cancer, highlighting the effectiveness of mice in preclinical cancer research.

The team found multiple drugs and drug combinations that were effective against human colon cancer cells. These are promising results for alternative second- or third-line treatments after resistance to the first round of treatment against this occurs.

"Our results illustrate the power of combining genomic information with large-scale drug screening to provide new targeted treatment strategies for patients with specific cancer subtypes," says Dr Ultan McDermott, author from the Wellcome Trust Sanger Institute.


'/>"/>

Contact: Aileen Sheehy
press.office@sanger.ac.uk
44-012-234-96928
Wellcome Trust Sanger Institute
Source:Eurekalert

Related medicine news :

1. Telesoft the Subject of a Strengths, Weaknesses, Opportunities, and Threats Report
2. Newly Released Continuing Education Courses Provide Physical and Occupational Therapy Professionals With Opportunities To Expand Skill Sets
3. Critical Acclaim Pouring in for Killing Ideas: You Can Kill an Idea, You Can’t Kill an Opportunity by Dr. Pam Henderson: Book Shows Companies How to Maximize Growth Through BIG Opportunities
4. AGA presents cutting-edge research and new learning opportunities at DDW® 2013
5. Large genomic study identifies endometrial cancer subtypes, treatment opportunities
6. New Career Opportunities Appear in the Emerging Semi Permanent Make-up Market with Long-Time-Liner®’s Semi Permanent Make-up Training Courses
7. Extracellular vesicles may open new opportunities for brain cancer diagnosis and treatment
8. Laser Die-Cutting Creates New Opportunities for Acrylic Photo Gifts
9. General Plastics Announces Global Distribution Opportunities
10. Lice Happens Now Offering "Lousy" Franchise Opportunities
11. MMS Group Explores New Opportunities for Placing Healthcare Contractors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: